EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impact of pharmacological sGC stimulation with Riociguat in experimental models of liver disease regression

Katharina Bonitz, Philipp Königshofer, Henriette Horstmeier, Thomas Sorz-Nechay, Vlad Taru, Katharina Bareiner, Oleksander Petrenko, Benedikt Simbrunner, Benedikt Silvester Hofer, Georg Kramer, Katja Sommer, Kerstin Zinober und 8 weitere

Hepatology International · 2026

DOI: 10.1007/s12072-026-11086-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hepatology International, 2026. Verfasst von Katharina Bonitz und 19 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austri…. Hauptthemen laut MEDLINE: Pyrimidines, Pyrazoles, Soluble Guanylyl Cyclase, Liver Cirrhosis. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Christian Doppler Forschungsgesellschaft, Medical University of Vienna.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Liver fibrosis and portal hypertension (PH) determine prognosis in chronic liver disease. In experimental models, stimulation of NO–sGC–cGMP signaling improved fibrosis, PH and inflammation. Since fibrosis and PH improve slowly after injury cessation, we investigated whether stimulating sGC activity accelerates their regression.

Methods

Liver fibrosis was induced in C57BL/6 J mice by either carbon tetrachloride (CCl 4 ; 2 µl/g, gavage 3x/week) for 12 weeks or thioacetamide (TAA; 150 mg/kg, intraperitoneal injections 3x/week) for 12 weeks, followed by 1 (R1) or 2 (R2) weeks of regression. Animals received the sGC stimulator Riociguat (RIO; 3 mg/kg, gavage 2x/day) during regression. Disease severity was assessed by portal pressure (PP), collagen proportionate area (CPA) and whole liver transcriptomics.

Results

PH and fibrosis area peaked in the TAA model at 7.71 ± 0.57 mmHg PP and 3.87 ± 0.19% CPA; and in the CCl 4 model at 9.06 ± 0.89 mmHg PP and 9.43 ± 2.59% CPA, respectively; followed by spontaneous regression at R2 (TAA: PP: 6.04 ± 0.52 mmHg, CPA: 2.90 ± 0.30%; CCl 4 : PP: 5.88 ± 0.52 mmHg, CPA: 6.66 ± 1.45%). RIO significantly increased hepatic cGMP levels (CCl 4 –R2: 5.89 ± 0.58 nmol/L, R2 + RIO: 12.41 ± 1.98 nmol/L). While fibrosis and PH regression were not significantly different, RIO treatment attenuated the hepatic pro-inflammatory gene signatures in both models and improved metabolic pathways on a transcriptional level.

Conclusions

Riociguat increases hepatic cGMP bioavailability and mitigates inflammatory and metabolic gene signatures in two experimental models of regressive liver disease. While regression of liver fibrosis and PH was not accelerated by Riociguat, our results suggest beneficial effects of sGC stimulation during regressive liver disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyrimidinesPyrazolesSoluble Guanylyl CyclaseLiver CirrhosisHypertension, PortalAnimalsMiceMice, Inbred C57BLDisease Models, AnimalMaleCarbon TetrachlorideLiverThioacetamideCyclic GMP

Stichwörter der Autor:innen

Experimental fibrosisLiver fibrosis regressionLiver transcriptomicsPortal hypertensionRiociguatSoluble guanylyl cyclase

Substanzen

PyrimidinesPyrazolesriociguatSoluble Guanylyl CyclaseCarbon TetrachlorideThioacetamideCyclic GMP

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.
  • Hepatic Experimental Hemodynamic Lab (HEPEX) Lab, Medical University of Vienna, Vienna, Austria.
  • Christian-Doppler Laboratory for Portal Hypertension and Liver Fibrosis, Medical University of Vienna, Vienna, Austria.
  • CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
  • Clinical Institute of Medical and Chemical Laboratory Diagnostics, Graz, Austria.
  • CardioRenalMetabolic Diseases Research, Boehringer Ingelheim Pharma GmbH & Co.KG, Biberach an Der Riss, Germany.

Förderung

  • Christian Doppler Forschungsgesellschaft
  • Medical University of Vienna

Zitieren

APA

Bonitz, K., Königshofer, P., Horstmeier, H., Sorz-Nechay, T., Taru, V., Bareiner, K., Petrenko, O., Simbrunner, B., Hofer, B. S., Kramer, G., Sommer, K., Zinober, K., Regnat, K., Scharnagl, H., Sun, P., Simon, E., Kauscke, S., Trauner, M., Reiberger, T., & Schwabl, P. (2026). Impact of pharmacological sGC stimulation with Riociguat in experimental models of liver disease regression. Hepatology International. https://doi.org/10.1007/s12072-026-11086-4

Vancouver

Bonitz K, Königshofer P, Horstmeier H, Sorz-Nechay T, Taru V, Bareiner K, et al. Impact of pharmacological sGC stimulation with Riociguat in experimental models of liver disease regression. Hepatology International. 2026. doi:10.1007/s12072-026-11086-4

BibTeX
@article{Bonitz2026,
  author = {Bonitz, Katharina and Königshofer, Philipp and Horstmeier, Henriette and Sorz-Nechay, Thomas and Taru, Vlad and Bareiner, Katharina and Petrenko, Oleksander and Simbrunner, Benedikt and Hofer, Benedikt Silvester and Kramer, Georg and Sommer, Katja and Zinober, Kerstin and Regnat, Katharina and Scharnagl, Hubert and Sun, Peng and Simon, Eric and Kauscke, Stefan and Trauner, Michael and Reiberger, Thomas and Schwabl, Philipp},
  title = {Impact of pharmacological sGC stimulation with Riociguat in experimental models of liver disease regression},
  journal = {Hepatology International},
  year = {2026},
  doi = {10.1007/s12072-026-11086-4}
}
Kostenlos starten →